Japan Drug Delivery Devices Market Insights Forecasts to 2032
- The Japan Drug Delivery Devices Market Size was valued at USD 3.18 Billion in 2022.
- The Market Size is Growing at a CAGR of 4.67% from 2022 to 2032.
- The Japan Drug Delivery Devices Market Size is Expected to Reach 5.02 Billion by 2032.
Get more details on this report -
The Japan Drug Delivery Devices Market Size is Expected to Reach USD 5.02 Billion by 2032, at a CAGR of 4.67% during the forecast period 2022 to 2032.
Drug Delivery Devices are medical devices that are used to administer medications to patients. Drug Delivery Devices have numerous medical and therapeutic applications for improving patients' conditions. Prefilled syringes autoinjectors, infusion pumps, metered dose inhalers (MDIs), nebulizers, nasal sprays, eye droppers, intrauterine devices (IUDs), and many other Drug Delivery Devices are available on the market. The drug delivery device is chosen by the healthcare professional based on the dosage form and the delivery requirements for any drug. A metered-dose inhaler (MDI), for example, is used to deliver medication for asthma, which disperses a precise amount of medication into the lungs to provide relief. A drug can be delivered in four ways: by swallowing, inhaling, absorption through the skin, or injection. Each drug delivery device uses one of these four methods to deliver the drug. It is critical to use an appropriate drug delivery device to reduce side effects and increase the level of a drug present at the target site.
This research report categorizes the market for Japan's drug delivery devices market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan drug delivery devices market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan drug delivery devices market.
Japan Drug Delivery Devices Market Report Coverage
|Market Size in 2022:
|USD 3.18 Billion
|2022 to 2032
|Forecast Period 2022 to 2032 CAGR:
|2032 Value Projection:
|USD 5.02 Billion
|Historical Data for:
|No. of Pages:
|Tables, Charts & Figures:
|By Route, By Application, By End Users,
|Mylan N.V., Antares Pharma, Inc., Tasei Kako Co. Ltd., GlaxoSmithKline Plc, Novartis AG, Bayer AG, Becton, Dickinson, and Company, Johnson & Johnson, 3M Company, Others, and
|Pitfalls & Challenges:
|COVID-19 Empact, Challenge, Future, Growth, & Analysis
Get more details on this report -
The rising prevalence of chronic diseases is expected to drive market growth during the forecast period. The rapid expansion of the healthcare sector is a major factor driving market growth. Furthermore, R&D investment and technological advancement in drug delivery devices are expected to provide market participants with numerous opportunities.
The main challenge that can hinder market growth is inefficiency in delivering poorly soluble drugs. Strict government rules and regulations concerning drug delivery devices are expected to hamper market growth during the forecast period.
- In 2022, the oral segment accounted for the largest revenue share over the forecast period.
Based on the route of administrations, the Japan drug delivery devices market is segmented into ocular, topical, injectable, oral, and others. Among these, the oral segment has the largest revenue share over the forecast period. Oral drug delivery systems include a variety of dosage forms such as tablets, capsules, syrups, solutions, and suspensions. Distribution products such as films and tablets are also included in this segment. In terms of safety, ease of use, cost, and stability, the oral route is the preferred route of administration. In cases of pulmonary conditions such as asthma and chronic obstructive pulmonary disease (COPD), inhalation drug delivery systems are preferred. Factors such as the increasing prevalence of respiratory diseases and the technological advancement of inhalation devices such as nebulizers and inhalers are projected to propel the growth of this segment.
In 2022, the cancer segment is expected to hold a significant market share over the forecast period
Based on application, the Japan drug delivery devices market is segmented into cardiovascular, infectious diseases, cancer, diabetes, and others. Among these, the cancer segment is expected to hold a significant market share over the forecast period. Cancer is becoming more common, and the government is taking steps to raise awareness about cancer and its treatments.
- In 2022, the hospitals segment accounted for the largest revenue share over the forecast period.
Based on the end user, the Japan drug delivery devices market is segmented into hospitals, ambulatory surgical centers, and others. Among these, the hospitals segment has the largest revenue share over the forecast period. Cancer, diabetes, and neurological disorders are on the rise. Patients admitted to the hospital with various disorders require different drugs for treatment, which are administered via various drug-delivery devices. However, hospital-acquired infection is expected to have an impact on the adoption of drug-delivery devices in hospitals, potentially slowing segment growth during the forecast period.
The report offers the appropriate analysis of the key organizations/companies involved within the Japan drug delivery devices market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Mylan N.V.
- Antares Pharma, Inc.
- Tasei Kako Co. Ltd.
- GlaxoSmithKline Plc
- Novartis AG
- Bayer AG
- Becton, Dickinson, and Company
- Johnson & Johnson
- 3M Company
Key Target Audience
- Market Players
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
This study forecasts revenue at regional, and country levels from 2021 to 2032. Spherical Insights has segmented the Japan Drug Delivery Devices Market based on the below-mentioned segments:
Japan Drug Delivery Devices Market, By Route of Administration
Japan Drug Delivery Devices Market, By Application
- Infectious Diseases
Japan Drug Delivery Devices Market, By End User
- Ambulatory Surgical Centers
Need help to buy this report?